Clinical Trial Update: Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 safety study of iSONEP (sonepcizumab/LT1009) for neovascular age-related macular degeneration, sponsored by Lpath…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• iSONEP (Sonepcizumab)

Snippet

Sponsor: Lpath, Inc. | Conditions: Neovascular Age Related Macular Degeneration | Phase 1 | Status: UNKNOWN